Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome

• Autores: John A. Zic
• Localización: Dermatologic clinics, ISSN 0733-8635, Vol. 33, Nº. 4, 2015 (Ejemplar dedicado a: Cutaneous Lymphoma), págs. 765-776
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Extracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to an expansion of peripheral blood dendritic cell populations and an enhanced TH1 immune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side effect profile and moderate efficacy, ECP is considered first-line therapy for erythrodermic mycosis fungoides (MF) and Sézary syndrome. Patients with a measurable but low blood tumor burden are most likely to respond to ECP, and the addition of adjunctive immunostimulatory agents may also increase response rates. There may be a role for ECP in the treatment of refractory early stage MF, but data are limited.